MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO)

Research output: Contribution to journalReview article

370 Citations (Scopus)

Abstract

BACKGROUND Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. METHODS A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. RESULTS The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines. CONCLUSIONS The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.

Original languageEnglish (US)
Pages (from-to)1453-1461
Number of pages9
JournalCancer
Volume120
Issue number10
DOIs
StatePublished - May 15 2014

Fingerprint

Mucositis
Medical Oncology
Practice Management
Practice Guidelines
Guidelines
Neoplasms
Stomatitis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO) (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 120(10), 1453-1461. https://doi.org/10.1002/cncr.28592

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. / The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO).

In: Cancer, Vol. 120, No. 10, 15.05.2014, p. 1453-1461.

Research output: Contribution to journalReview article

The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO) 2014, 'MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy', Cancer, vol. 120, no. 10, pp. 1453-1461. https://doi.org/10.1002/cncr.28592
The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014 May 15;120(10):1453-1461. https://doi.org/10.1002/cncr.28592
The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO). / MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. In: Cancer. 2014 ; Vol. 120, No. 10. pp. 1453-1461.
@article{934d1ea9b2ff4b9abd4f0d4db4656113,
title = "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy",
abstract = "BACKGROUND Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. METHODS A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. RESULTS The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines. CONCLUSIONS The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.",
author = "{The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO)} and Lalla, {Rajesh V.} and Joanne Bowen and Andrei Barasch and Linda Elting and Joel Epstein and Keefe, {Dorothy M.} and McGuire, {Deborah B.} and Cesar Migliorati and Ourania Nicolatou-Galitis and Peterson, {Douglas E.} and Raber-Durlacher, {Judith E.} and Sonis, {Stephen T.} and Sharon Elad and Noor Al-Dasooqi and Michael Brennan and Rachel Gibson and Janet Fulton and Ian Hewson and Jensen, {Siri B.} and Richard Logan and {\"O}hrn, {Kerstin E.O.} and Triantafyllia Sarri and Deborah Saunders and Cesar Migliorati and Noam Yarom and Justin Allemano and Al-Azri, {Abdul Rahman} and Antunes, {Heliton Spindola} and Anura Ariyawardana and Emma Bateman and Nicole Blijlevens and Boers-Doets, {Christine B.} and Paolo Bossi and Brown, {Carlton G.} and Chang, {Yu Chia} and Cheng, {Karis K.} and Catherine Cooksley and Correa, {Elvira P.} and Kristopher Dennis and {Di Palma}, Mario and Scott Drucker and June Eilers and Carmen Escalante and Estilo, {Cherry L.} and Hele Everaus and Margot Fijlstra and Monica Fliedner and Annette Freidank and Erich Gerber and Faith Gibson",
year = "2014",
month = "5",
day = "15",
doi = "10.1002/cncr.28592",
language = "English (US)",
volume = "120",
pages = "1453--1461",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

AU - The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO)

AU - Lalla, Rajesh V.

AU - Bowen, Joanne

AU - Barasch, Andrei

AU - Elting, Linda

AU - Epstein, Joel

AU - Keefe, Dorothy M.

AU - McGuire, Deborah B.

AU - Migliorati, Cesar

AU - Nicolatou-Galitis, Ourania

AU - Peterson, Douglas E.

AU - Raber-Durlacher, Judith E.

AU - Sonis, Stephen T.

AU - Elad, Sharon

AU - Al-Dasooqi, Noor

AU - Brennan, Michael

AU - Gibson, Rachel

AU - Fulton, Janet

AU - Hewson, Ian

AU - Jensen, Siri B.

AU - Logan, Richard

AU - Öhrn, Kerstin E.O.

AU - Sarri, Triantafyllia

AU - Saunders, Deborah

AU - Migliorati, Cesar

AU - Yarom, Noam

AU - Allemano, Justin

AU - Al-Azri, Abdul Rahman

AU - Antunes, Heliton Spindola

AU - Ariyawardana, Anura

AU - Bateman, Emma

AU - Blijlevens, Nicole

AU - Boers-Doets, Christine B.

AU - Bossi, Paolo

AU - Brown, Carlton G.

AU - Chang, Yu Chia

AU - Cheng, Karis K.

AU - Cooksley, Catherine

AU - Correa, Elvira P.

AU - Dennis, Kristopher

AU - Di Palma, Mario

AU - Drucker, Scott

AU - Eilers, June

AU - Escalante, Carmen

AU - Estilo, Cherry L.

AU - Everaus, Hele

AU - Fijlstra, Margot

AU - Fliedner, Monica

AU - Freidank, Annette

AU - Gerber, Erich

AU - Gibson, Faith

PY - 2014/5/15

Y1 - 2014/5/15

N2 - BACKGROUND Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. METHODS A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. RESULTS The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines. CONCLUSIONS The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.

AB - BACKGROUND Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. METHODS A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. RESULTS The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines. CONCLUSIONS The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84899950755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899950755&partnerID=8YFLogxK

U2 - 10.1002/cncr.28592

DO - 10.1002/cncr.28592

M3 - Review article

VL - 120

SP - 1453

EP - 1461

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -